Newsbenzinga
Novo Nordisk Says Anti-Inflammatory Drug Trial Fails to Cut Cardiovascular Risk in High Risk Patients
· Published
Article summary
Novo Nordisk Phase 3 ZEUS trial shows ziltivekimab missed MACE risk reduction. Operating profit outlook unchanged despite Q3 impairment.
An excerpt from the original article.
Comments —
Loading comments…